Philogen IPO a No-Go After Bayer Nixes Antibody Deal
LONDON Philogen SpA pulled its initial public offering on the Milan Stock Exchange after partner Bayer Schering Pharma AG peremptorily terminated a licensing and collaboration deal between the two for the development of vascular-targeting antibodies in the treatment of cancer.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.